QQQ   289.58 (-0.54%)
AAPL   137.35 (-2.46%)
MSFT   253.14 (-0.37%)
FB   191.29 (-0.49%)
GOOGL   2,207.68 (-1.35%)
AMZN   2,146.38 (+0.19%)
TSLA   709.42 (-0.05%)
NVDA   171.24 (+1.10%)
BABA   87.69 (+0.44%)
NIO   16.66 (+5.24%)
AMD   96.67 (+0.41%)
CGC   5.87 (+5.01%)
MU   69.40 (-2.32%)
T   20.21 (-0.10%)
GE   75.74 (+0.72%)
F   12.85 (+0.55%)
DIS   103.14 (-1.11%)
AMC   13.08 (+2.51%)
PFE   50.65 (+0.50%)
PYPL   81.28 (+5.31%)
NFLX   183.48 (+3.55%)
QQQ   289.58 (-0.54%)
AAPL   137.35 (-2.46%)
MSFT   253.14 (-0.37%)
FB   191.29 (-0.49%)
GOOGL   2,207.68 (-1.35%)
AMZN   2,146.38 (+0.19%)
TSLA   709.42 (-0.05%)
NVDA   171.24 (+1.10%)
BABA   87.69 (+0.44%)
NIO   16.66 (+5.24%)
AMD   96.67 (+0.41%)
CGC   5.87 (+5.01%)
MU   69.40 (-2.32%)
T   20.21 (-0.10%)
GE   75.74 (+0.72%)
F   12.85 (+0.55%)
DIS   103.14 (-1.11%)
AMC   13.08 (+2.51%)
PFE   50.65 (+0.50%)
PYPL   81.28 (+5.31%)
NFLX   183.48 (+3.55%)
QQQ   289.58 (-0.54%)
AAPL   137.35 (-2.46%)
MSFT   253.14 (-0.37%)
FB   191.29 (-0.49%)
GOOGL   2,207.68 (-1.35%)
AMZN   2,146.38 (+0.19%)
TSLA   709.42 (-0.05%)
NVDA   171.24 (+1.10%)
BABA   87.69 (+0.44%)
NIO   16.66 (+5.24%)
AMD   96.67 (+0.41%)
CGC   5.87 (+5.01%)
MU   69.40 (-2.32%)
T   20.21 (-0.10%)
GE   75.74 (+0.72%)
F   12.85 (+0.55%)
DIS   103.14 (-1.11%)
AMC   13.08 (+2.51%)
PFE   50.65 (+0.50%)
PYPL   81.28 (+5.31%)
NFLX   183.48 (+3.55%)
QQQ   289.58 (-0.54%)
AAPL   137.35 (-2.46%)
MSFT   253.14 (-0.37%)
FB   191.29 (-0.49%)
GOOGL   2,207.68 (-1.35%)
AMZN   2,146.38 (+0.19%)
TSLA   709.42 (-0.05%)
NVDA   171.24 (+1.10%)
BABA   87.69 (+0.44%)
NIO   16.66 (+5.24%)
AMD   96.67 (+0.41%)
CGC   5.87 (+5.01%)
MU   69.40 (-2.32%)
T   20.21 (-0.10%)
GE   75.74 (+0.72%)
F   12.85 (+0.55%)
DIS   103.14 (-1.11%)
AMC   13.08 (+2.51%)
PFE   50.65 (+0.50%)
PYPL   81.28 (+5.31%)
NFLX   183.48 (+3.55%)
NASDAQ:LRMR

Larimar Therapeutics (LRMR) Stock Forecast, Price & News

$2.69
+0.08 (+3.07%)
(As of 05/19/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.64
$2.71
50-Day Range
$2.51
$4.46
52-Week Range
$2.40
$15.49
Volume
15,581 shs
Average Volume
160,684 shs
Market Capitalization
$47.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.14
30 days | 90 days | 365 days | Advanced Chart
Receive LRMR News and Ratings via Email

Sign-up to receive the latest news and ratings for Larimar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Larimar Therapeutics logo

About Larimar Therapeutics

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics, Inc. is headquartered in Bala Cynwyd, Pennsylvania.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LRMR
Fax
N/A
Employees
31
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$3.22 per share

Profitability

Net Income
$-50.64 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
16,529,000
Market Cap
$47.64 million
Optionable
Not Optionable

Company Calendar

Last Earnings
3/25/2022
Today
5/19/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.91 out of 5 stars

Medical Sector

698th out of 1,418 stocks

Pharmaceutical Preparations Industry

333rd out of 677 stocks

Analyst Opinion: 3.2Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -













Larimar Therapeutics (NASDAQ:LRMR) Frequently Asked Questions

Is Larimar Therapeutics a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Larimar Therapeutics in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Larimar Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LRMR, but not buy additional shares or sell existing shares.
View analyst ratings for Larimar Therapeutics
or view top-rated stocks.

When is Larimar Therapeutics' next earnings date?

Larimar Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Larimar Therapeutics
.

How were Larimar Therapeutics' earnings last quarter?

Larimar Therapeutics, Inc. (NASDAQ:LRMR) posted its quarterly earnings results on Friday, March, 25th. The company reported ($0.50) EPS for the quarter.
View Larimar Therapeutics' earnings history
.

What price target have analysts set for LRMR?

3 analysts have issued 12-month price targets for Larimar Therapeutics' shares. Their forecasts range from $3.00 to $8.00. On average, they expect Larimar Therapeutics' share price to reach $5.50 in the next twelve months. This suggests a possible upside of 104.5% from the stock's current price.
View analysts' price targets for Larimar Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Larimar Therapeutics' key executives?
Larimar Therapeutics' management team includes the following people:
  • Dr. Carole S. Ben-Maimon, CEO, Pres & Director (Age 63, Pay $723.01k)
  • Mr. Michael Celano, Chief Financial Officer (Age 63, Pay $433.98k)
  • Mr. John Berman, VP of Fin. & Operations
  • Ms. Jennifer Spokes Johansson, VP of Regulatory Affairs & Counsel
  • Dr. Nancy M. Ruiz, Chief Medical Officer
  • Mr. Francis Michael Conway, VP & Controller
What is Larimar Therapeutics' stock symbol?

Larimar Therapeutics trades on the NASDAQ under the ticker symbol "LRMR."

Who are Larimar Therapeutics' major shareholders?

Larimar Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (7.24%), Vanguard Group Inc. (2.89%), Verition Fund Management LLC (2.40%), Renaissance Technologies LLC (0.98%), Ghost Tree Capital LLC (0.56%) and Golden State Equity Partners (0.17%).
View institutional ownership trends for Larimar Therapeutics
.

Which major investors are selling Larimar Therapeutics stock?

LRMR stock was sold by a variety of institutional investors in the last quarter, including Ghost Tree Capital LLC, RA Capital Management L.P., Renaissance Technologies LLC, and Vanguard Group Inc..
View insider buying and selling activity for Larimar Therapeutics
or view top insider-selling stocks.

Which major investors are buying Larimar Therapeutics stock?

LRMR stock was purchased by a variety of institutional investors in the last quarter, including Verition Fund Management LLC, and Golden State Equity Partners.
View insider buying and selling activity for Larimar Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Larimar Therapeutics?

Shares of LRMR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Larimar Therapeutics' stock price today?

One share of LRMR stock can currently be purchased for approximately $2.69.

How much money does Larimar Therapeutics make?

Larimar Therapeutics has a market capitalization of $47.64 million. The company earns $-50.64 million in net income (profit) each year or ($2.700010) on an earnings per share basis.

How many employees does Larimar Therapeutics have?

Larimar Therapeutics employs 31 workers across the globe.

What is Larimar Therapeutics' official website?

The official website for Larimar Therapeutics is larimartx.com.

How can I contact Larimar Therapeutics?

Larimar Therapeutics' mailing address is THREE BALA PLAZA EAST. SUITE 506, BALA CYNWYD PA, 19004. The company can be reached via phone at (844) 511-9056 or via email at [email protected].

This page was last updated on 5/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.